Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 18/20 | 0.72 |
| ▸ | PLG | P00747 | 2/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23934123 | 1.00 | FOLH1 (0.72) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL24375484 | 0.98 | FOLH1 (0.69) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL24374962 | 0.93 | FOLH1 (0.73) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL24374923 | 0.93 | FOLH1 (0.73) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL23453213 | 0.93 | FOLH1 (0.73) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL23453197 | 0.92 | FOLH1 (0.73) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL27304711 | 0.88 | FOLH1 (0.77) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL21555403 | 0.88 | FOLH1 (0.73) | FOLH1 | |
| SCHEMBL21310703 | 0.88 | FOLH1 (0.82) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL22883225 | 0.88 | FOLH1 (0.82) | FOLH1PLGPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125957-A1 | METHODS OF TREATING CANCER | SATHEKGE MIKE (ZA) | 2022-04-28 | — | — | US | disclosed |
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE INC (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125957-A1 | METHODS OF TREATING CANCER | PAICS, FOLH1, INHA | FOLH1 2/4885PLG 810/4885PRSS1 3798/4885 |
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | PSMA6, PSMA2, PSMA1 | FOLH1 10/4885PLG 2700/4885PRSS1 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.